quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom

View original at nasdaq.com
“TSMC anticipates its operating profit margin to be 57.5% in Q2 (at the midpoint of its guidance range).”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia anticipates $1 trillion in AI data center chip sales in 2026 and 2027

    60% confidence
  • TSMC could be the ultimate pick-and-shovel AI stock for 2026 and beyond due to its wider reach in AI chips than Nvidia and Broadcom

    60% confidence
  • TSMC expects revenue to increase by more than 30% in 2026, revised from earlier forecast of close to 30%

    60% confidence
  • Broadcom sees $100 billion in AI chip revenue in fiscal 2027, up from $20 billion in fiscal 2025

    60% confidence
  • TSMC anticipates operating profit margin of 57.5% in Q2 2026 at the midpoint of guidance range

    60% confidence
  • TSMC is expected to continue raising prices for its advanced chip nodes over the next four years

    60% confidence
  • Stock Advisor's total average return is 994%, outperforming the S&P 500's 199%

    60% confidence
  • TSMC forecasts 32% year-over-year revenue increase in Q2 2026 to $39.6 billion

    60% confidence

Data points we hold from this source

Taiwan Semiconductor Manufacturing Company · forward earnings multiple25 ratio
Taiwan Semiconductor Manufacturing Company · net profit margin50.5 percent
Taiwan Semiconductor Manufacturing Company · eps3.49 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com